This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Leadiant fails to end Spanish probe into dominance abuse with commitments

( June 22, 2022, 15:47 GMT | Official Statement) -- MLex Summary: Drgumaker Leadiant Biosciences saw the Spanish competition authority reject commitments to end an antitrust probe over its alleged abuse of dominance in the production and supply of its orphan drug CDCA-Leadiant. According to a resolution published today, the watchdog rejected two rounds of commitments and ended the settlement procedure. Leadiant challenged the latter decision, but the CNMC rejected the appeal.See resolution in Spanish attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections